Association of Treatment With 5α-Reductase Inhibitors and Prostate Cancer Mortality Among Older Adults
- Read more about Association of Treatment With 5α-Reductase Inhibitors and Prostate Cancer Mortality Among Older Adults
- Log in or register to post comments
5α-reductase inhibitors (5-ARIs) are used to treat benign prostatic enlargement, a common condition causing urinary outflow obstruction. They also reduce prostate-specific antigen (PSA) by approximately 50%. Our group has recently published that among US military veterans, 5-ARIs are associated with delays in prostate cancer (PC) diagnoses, higher grade and stage at presentation, and worse PC-specific mortality (PCSM), presumably because of misinterpreted PSA values. We hypothesized that these results are generalizable to the broader US population.